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doi:10.101Impact of Cytomegalovirus (CMV) Reactivation
after Umbilical Cord Blood Transplantation
Jill C. Beck,1 John E. Wagner,1 Todd E. DeFor,1 Claudio G. Brunstein,2 Mark R. Schleiss,1
Jo-Anne Young,2 Daniel H. Weisdorf,2 Sarah Cooley,2 Jeffrey S. Miller,2 Michael R. Verneris1This study investigated the impact of pretransplant cytomegalovirus (CMV) serostatus and posttransplant
CMV reactivation and disease on umbilical cord blood transplant (UCBT) outcomes. Between 1994 and
2007, 332 patients with hematologic malignancies underwent UCBTand 54% were CMV seropositive. Pre-
transplant recipient CMV serostatus had no impact on acute or chronic graft-versus-host disease (aGVHD,
cGVHD), relapse, disease-free survival (DFS), or overall survival (OS). There was a trend toward greater day
100 treatment-related mortality (TRM) in CMV-seropositive recipients (P5.07). CMV reactivation occurred
in 51% (92/180) of patients with no difference in myeloablative (MA) versus reduced-intensity conditioning
(RIC) recipients (P5.33). Similarly, reactivation was not influenced by the number of UCB units transplanted,
the degree of HLA disparity, the CD341 or CD31 cell dose, or donor killer cell immunoglobulin-like recep-
tor (KIR) gene haplotype. Rapid lymphocyte recovery was associated with CMV reactivation (P5.02). CMV
reactivation was not associated with aGVHD (P5.97) or cGVHD (P5.65), nor did it impact TRM (P5.88),
relapse (P5.62), or survival (P5.78). CMV disease occurred in 13.8% of the CMV-seropositive patients, re-
sulting in higher TRM (P5.01) and lower OS (P5.02). Thus, although recipient CMV serostatus and CMV
reactivation have little demonstrable impact on UCB transplant outcomes, the development of CMV disease
remains a risk, associated with inferior outcomes.
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Umbilical cord blood (UCB) is increasingly being
used as an alternative donor source for hematopoietic
cell transplantation (HCT). Compared to bonemarrow
(BM), UCB is relatively simple and safe to collect, rap-
idly available, and has a decreased likelihood of trans-
mitting viral infections. UCB is associated with
a lower risk of severe graft-versus-host disease
(GVHD), despite significant HLA disparity between
donor and recipient [1]. Because UCB T cells are im-
munologically naı¨ve, they do not offer passive immunity
to the transplant recipient. Given these differences,1Department of Pediatrics;and 2Department of Medicine,
on of Blood and Marrow Transplantation, University of
esota, Minneapolis, Minnesota.
isclosure: See Acknowledgments on page 221.
dence and reprint requests: Michael R. Verneris, MD,
tment of Pediatrics, University of Minnesota, 425 East
Road, Suite 660, Minneapolis, MN 55455 (e-mail:
ris@umn.edu).
uly 13, 2009; accepted September 24, 2009
erican Society for Blood and Marrow Transplantation
/10/162-0008$36.00/0
6/j.bbmt.2009.09.019there have been concerns for prolonged reconstitution
of antigen specific immunity and increased risk for viral
infections after UCB transplantation [2,3]. In fact, some
studies show fewer cytomegalovirus (CMV)-specific
CD41 and CD81 T cells and a higher incidence of viral
infections following UCB transplant [4-7].
CMV is thought to contribute significantly to
HCT morbidity and mortality[3,8-10]. Risk factors
for CMV reactivation include prior CMV infection
in the donor or recipient, GVHD, steroid therapy,
T cell depletion, and age [10-16]. Unlike peripheral
blood (PB) or BM transplantation where CMV reac-
tivation can arise from either the donor or recipient,
after UCB transplantation, CMV is almost exclusively
because of reactivation of endogenous virus in the
host. This is because CMV infection in newborns is
rare, and infected UCB units are not generally
banked or used clinically [17]. To date, the incidence
and risk factors forCMV reactivation have not been ex-
tensively described post-UCB transplantation. Here
we report the incidence of CMV reactivation and its
impact on UCB transplant-associated outcomes. We
also explore risk factors for CMV reactivation in
CMV-seropositive recipients following UCB trans-
plantation.215
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Transplant Procedures
Myeloablative (MA) conditioning was used in 227
consecutive patients with malignant hematologic dis-
eases and consisted of cyclophosphamide (Cy;
60 mg/kg 2) and total body irradiation (TBI;
13.2 Gy, 165 cGy twice daily 4 days). From 1994
to 2000, this regimen included equine antithymocyte
globulin (ATG;AM Pharma NY, NY) 15 mg/kg every
12 hours on days23 to21 pretransplant, and methyl-
prednisolone (MP) (1 mg/kg every 12 hours from days
5 to 19) (n5 31). After 2000, ATG andmethylprednis-
olone were replaced with fludarabine (Flu; 25 mg/m2/
day) on day 28 through 26, and mycophenolate mo-
fetil (MMF; 1 g every 12 hours from day 23 to day
130) [18]. All patients also received cyclosporine A
(CsA) starting at day 23 and continuing for approxi-
mately 180 days. Following MA conditioning either
1 (n5 116) or 2 (n5 111) UCB units were infused.
Reduced-intensity conditioning (RIC) consisted of
Cy(50 mg/kg), Flu (200 mg/m2), and TBI (2 Gy).
RIC was followed by double UCBT in all patients
(n5 105) [19]. Patients undergoing RIC single
UCBT (n5 17), RIC double UCBT with ATG in
the preparative regimen (n5 4), and transplantation
for chronic lymphocytic leukemia (CLL) (n5 6)
were excluded from this analysis because of small num-
bers of patients in those categories.
GVHD Prophylaxis, Diagnosis, and Treatment
GVHD prophylaxis consisted of CsA/MMF
(n5 257) or Cy/MP/ATG (n5 75) [20]. Diagnosis
of acute and chronic GVHD (aGVHD, cGVHD)
was based on standard clinical criteria and biopsy
when available. Staging was based upon published cri-
teria [21], and treatment of aGVHD clinical stage II or
greater was with MP ($48 mg/m2 intravenously or
oral equivalent) daily for a minimum of 2 weeks prior
to a taper over 8 weeks.
CMV Screening and Prophylaxis
Prior to conditioning, all patients were assessed
for CMV exposure by serology using enzyme immu-
noassay. Patients with a CMV IgG antibody level
.10.0 EU/mL were considered positive. After trans-
plant, all patients underwent weekly screening for
CMV reactivation by either pp65 antigenemia (prior
to 2006) or PCR (after 2006) until day 1100 post-
UCBT. CMV-seropositive recipients received high-
dose acyclovir prophylaxis (500 mg/m2 [10-12 mg/
kg] i.v. every 8 hours or 800 mg [18 mg/kg pediatric]
orally 5 times daily) until day 100. CMV seronegative
recipients who were herpes simplex virus (HSV)-sero-
positive received low-dose acyclovir prophylaxis
(250 mg/m2 [5 mg/kg] i.v. every 12 hours or 400 mg[9 mg/kg pediatric] orally twice daily) until day 160.
CMV reactivation was defined as either CMV antige-
nemia ($2 pp65 positive cells/50,000), DNAemia
($500 copies by quantitative polymerase chain reac-
tion [PCR]), or culture of CMV from blood, body
fluid, or tissue. For the purposes of this analysis, the
maximum interval allowed for a single reactivation
episode was 30 days [22]. After clearance of CMV
for .30 days, a subsequent episode of CMV reactiva-
tion was considered an additional event. CMV reacti-
vation was treated with ganciclovir (induction [5 mg/
kg i.v. twice daily] for 2 weeks, followed by mainte-
nance [5 mg/kg i.v. daily] for an additional 6 weeks).
Foscarnet (induction [60 mg/kg i.v. every 8 hours],
followed by maintenance [90 mg/kg i.v. daily]) was
used in place of ganciclovir in patients prior to abso-
lute neutrophil count (ANC) recovery. All blood
products were CMV seronegative or leukoreduced
by filtration. CMV disease was defined as detection
of virus in end-organ tissues including lung (bron-
choalveolar lavage [BAL] sample) or gastrointestinal
(GI) tract (histopathologic changes consistent with
CMV).
Data Collection
Data regarding patient characteristics and out-
comes were prospectively collected by the Biostatisti-
cal Support Group at the University of Minnesota in
the HCT database. CMV serostatus and reactivation
data were assessed for completeness and accuracy by
retrospective review of patient records. Data was
analyzed retrospectively. Protocols were approved by
the University of Minnesota institutional review
board. All patients and/or their legal guardians pro-
vided institutional review board-approved signed in-
formed consent in accordance with the Declaration
of Helsinki.
Killer Cell Immunogloublin-like Receptor (KIR)
Gene Content Analysis
Thepresence or absence of 16KIRgeneswas deter-
mined using a high-throughput single nucleotide
polymorphism (SNP)-based Sequenom Mass array
system (Sequenom, San Diego, CA) and the matrix-
assisted laser desorption/ionization-time-of-flightmass
spectrometry (MALDI-TOF MS) platform for the
large-scale KIR genotyping of DNA samples as
previously described [23]. Samples with at least 1 KIR
B haplotype-defining locus (KIR2DL5, 2DS1, 2DS2,
2DS3, 2DS5, or 3DS1) were assigned the genotype
B/X and samples lacking all KIR B loci were assigned
the genotype A/A[23].
Statistical Analysis
Patient and transplant characteristics across
transplant type were compared using the chi-square
Biol Blood Marrow Transplant 16:215-222, 2010 217Impact of CMV Reactivation after UCB Transplantationtest or Fisher’s exact test. Continuous factors were
compared using the general Wilcoxon test. The pri-
mary end point was the cumulative incidence of
CMV reactivation. Other end points included overall
survival (OS), disease relapse, treatment-related mor-
tality (TRM), aGVHD, and cGVHD. The cumula-
tive incidence of CMV reactivation, disease relapse,
aGVHD, and cGVHD were calculated by treating
deaths from other causes as competing risks
[24]. The cumulative incidence of TRM was calcu-
lated by treating relapse as a competing risk. The
statistical end point of survival was estimated by
the Kaplan-Meier method [25]. Statistical compari-
son of the time-to-event curves between groups
was completed by the Log-Rank test. The time-
dependent effect of CMV reactivation on OS, disease
relapse, TRM, aGVHD, and cGVHD was assessed
using Cox regression analysis.
A Cox proportional hazards model was used to
model the independent effect of potential predictors
of CMV reactivation including: age (0-10 years versus
11-17 years versus 18-35 years versus 361 years),
weight, cell dose (quartiles of TNC, CD341, and
CD31), disease risk (standard versus high), condition-
ing regimen, number of UCB units, HLA disparity (4/
6 versus 5/6 versus 6/6), GVHD prophylaxis, time-
dependent GVHD, and sex [26].Table 1. Characteristics of All Patients Based on Pretransplant CM
Variable CMV-Positive R
Overall 180 (54
Conditioning regimen and number of UCB units
Myeloablative single (Cy/Flu/TBI) 25 (14
Myeloablative single (Cy/TBI/ATG) 31 (17
Myeloablative double (Cy/Flu/TBI) 66 (37
RIC double (Cy/Flu/TBI) 58 (32
HLA disparity (engrafting unit)
4/6 79 (47
5/6 72 (43
6/6 16 (10
Age
0-10 29 (16
11-17 33 (18
18-35 48 (27
35+ 70 (39
Sex
Male 103 (57
Female 77 (43
Diagnosis
Acute leukemia 125 (69
Other leukemia/MDS 16 (9%
Lymphoma 34 (19
Other malignancy 6 (3%
Disease Risk
Standard 70 (39
High 110 (61
GVHD Prophylaxis
CsA/MMF 149 (83
CsA/methylprednisone/ATG 31 (17
CMV indicates cytomegalovirus; UCB, umbilical cord blood; Cy, cyclophospha
syndrome; GVHD, graft-verus-host disease; CsA, cyclosporine; MMF, mycoph
Standard risk disease5 acute leukemia first complete remission (CR1), MDS,RESULTS
Patient Characteristics
Between 1994 and 2007, 332 patients underwent
HCT for hematologic malignancies using UCB at
the University of Minnesota. Prior to transplant,
54% of patients (n5 180) were CMV seropositive
and 46% (n5 152) were CMV seronegative. Patient
characteristics for these patients are summarized in
Table 1. CMV seronegative patients were more likely
to have high-risk disease and GVHD prophylaxis con-
sisting of CsA/MP/ATG. The 2 groups were similar
with respect to age, number of cord blood units
(CBUs) used, conditioning regimen, HLA disparity,
sex, and diagnosis.Predictors of CMV Reactivation in CMV
Seropositive Recipients
The incidence of CMV reactivation was 51% (92/
180) among CMV-seropositive transplant recipients.
Among CMV seronegative recipients, the incidence
of CMV infection was 1.3% (2/152), and these recipi-
ents were not analyzed further. The median time to
CMV reactivation was 40 days (range: 9-95 days). As
shown in Table 2, there was a similar time to reactiva-
tion regardless of conditioning regimen and number ofV Exposure
ecipient CMV-Negative Recipient P
%) 152 (46%)
.07
%) 16 (10%)
%) 44 (29%)
%) 45 (30%)
%) 47 (31%)
.74
%) 65 (47%)
%) 63 (46%)
%) 10 (7%)
.07
%) 38 (25%)
%) 17 (11%)
%) 33 (22%)
%) 64 (42%)
.46
%) 93 (61%)
%) 59 (39%)
.67
%) 104 (68%)
) 18 (12%)
%) 28 (18%)
) 2 (1%)
.04
%) 43 (28%)
%) 109 (72%)
.01
%) 108 (71%)
%) 44 (29%)
mide; Flu, fludarabine; TBI, total body irradiation; MDS, myelodysplastic
enolate mofetil; ATG, antithymocyte globulin.
CML CP1.
Table 2. Incidence of CMV Reactivation (in Pretransplant CMV Seropositive Patients) Through day 100
Variable All No. of Events Day 100 CMV Reactivation (95% CI) Median Days to CMV Reactivation (Range) P
Overall 180 92 51% (43%-59%) 40 (9-95)
Type .33
Full single (Cy/Flu/TBI) 25 9 36% (17%-55%) 40 (18-56)
Full single (Cy/TBI/ATG) 31 14 45% (27%-63%) 33.5 (11-56)
Full double (Cy/Flu/TBI) 66 35 53% (40%-66%) 39 (9-95)
RIC double (Cy/Flu/TBI) 58 34 59% (45%-73%) 43.5 (12-83)
HLA disparity (engrafting unit) .22
4/6 79 45 57% (45%-69%) 39 (9-95)
5/6 72 33 46% (34%-58%) 38 (12-82)
6/6 16 9 56% (30%-82%) 45 (12-83)
Age .04
0-10 29 11 38% (20%-56%) 38 (12-55)
11-17 33 14 42% (25%-59%) 32 (9-95)
18-35 48 25 52% (36%-68%) 43 (18-84)
35+ 70 42 60% (47%-73%) 43 (12-82)
Sex .57
Male 103 51 50% (40%-60%) 38 (9-84)
Female 77 41 53% (41%-65%) 43 (11-95)
Disease risk .48
Standard 70 35 50% (38%-62%) 44 (9-95)
High 110 57 52% (42%-64%) 39 (11-83)
TNC (total 107/kg) .75
First quartile 44 22 50% (34%-66%) 42.5 (12-70)
Second quartile 46 24 52% (36%-68%) 43.5 (9-83)
Third quartile 43 23 53% (37%-69%) 34 (19-95)
Fourth quartile 47 23 49% (34%-64%) 38 (12-77)
CD34 (total 105/kg) .12
First quartile 40 17 43% (27%-59%) 44 (28-76)
Second quartile 39 23 59% (42%-76%) 39 (11-82)
Third qauartile 40 19 48% (32%-64%) 46 (9-84)
Fourth quartile 42 25 60% (34%-76%) 34 (12-95)
CD3 (total 105/kg) .82
First quartile 35 16 46% (30%-62%) 35.5 (11-56)
Second quartile 41 24 59% (42%-75%) 39 (19-76)
Third quartile 42 22 52% (46%-68%) 43 (9-83)
Fourth quartile 41 22 54% (37%-71%) 36.5 (12-95)
ALC (total 108/L) .02*
<2.0 60 22 37% (25%-49%) 45 (22-83)
$2.0 100 61 61% (50%-72%) 38 (9-95)
Missing 20 9 15% (0%-38%) 40 (12-56)
CMV indicates cytomegalovirus; Cy, cyclophosphamide; Flu, fludarabine; TBI, total body irradiation; TNC, total nucleated cells; ALC, absolute leukocyte
count; CI, confidence interval.
*P-value only compares nonmissing groups.
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unit, recipient age, sex, or disease risk.
There was no difference in CMV reactivation for
recipients of an MA versus RIC transplant (P5 .33)
(Figure 1). CMV reactivation (38% versus 52%,
P5 .93) and disease (0% versus 15%, P5 .60) were
similar regardless of whether the SCT occurred from
1994-1999 or 2000-2007. CMV reactivation was sim-
ilar regardless of GVHD prophylaxis regimen (P5 .8)
(Figure 2). Likewise, in multivariate analysis, neither
aGVHD (relative risk [RR]5 1.0 [95% CI 0.5-2.0]),
P5 .97) nor cGVHD (RR5 1.2 [95% CI 0.6-2.1],
P5 .65) had an impact on CMV reactivation.
The infused T cell content did not influence CMV
reactivation (P5 .82). In contrast, lymphocyte recov-
ery was associated with CMV reactivation. Patients
with an absolute lymphocyte count (ALC)
.0.2 108/L at day 28 posttransplant (n5 100)
were more likely to have CMV reactivation compared
to those with ALC\0.2 108/L (n5 60) (61% [95%CI 50%-72%] versus 37% [95% CI 25%-49%]
P5 .02). CMV reactivation did not have an impact
on secondary graft failure. Among patients with
CMV reactivation, 2.2% (2/92) had secondary graft
failure compared to 3.4% (3/88) of patients who did
not experience CMV reactivation (P5 .62).
Donor KIR haplotype (A/A versus B/X) was deter-
mined in a subset of samples where DNA was available
for KIR typing (n5 65). Twenty patients engrafted
with KIR A/A haplotype donor and 55% (11/20) had
CMV reactivation, whereas 58% (26/45) of those en-
grafted with a KIR B/X donor showed reactivation.
Thus, donor KIR haplotype appeared to not have an
impact on recipient CMV reactivation (P5 .83).
Additional variables not associated with CMV re-
activation were sex (P5 .57), disease risk (standard
versus high, P5 .48), conditioning regimen
(P5 .33), and cell dose/kg, defined as total nucleated
cells/kg (P5 .75) or CD341/kg (P5 .12). There was
a trend toward increased age having an impact on
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Figure 1. Cumulative incidence of CMV reactivation by conditioning
regimen. There is no significant difference between the myeloablative
and nonmyeloablative conditioning.
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patients 18 years and older having a relative risk of
CMV reactivation of 1.5 (95% CI 1.0-2.5, P5 .06).Impact of Recipient CMV Seropositivity on
UCBTOutcomes
Recipient CMV-positive serostatus is frequently
associated with inferior transplant outcomes [9,27-
30]. The impact of pretransplant CMV serostatus
was determined on transplant-related outcomes. Al-
though CMV seropositive recipients showed a trend
toward greater day 100 TRM (P5 .07), CMV serosta-
tus was not associated with aGVHD (P5 .8), cGVHD
(P5 .24), OS (P5 .55), or disease relapse (P5 .78)
(Table 3).Impact of CMV Reactivation on Transplant-
Associated Outcomes for CMV-Seropositive
Recipients
We next analyzed whether CMV reactivation had
an impact on transplant-related outcomes. CMV reac-
tivation was not associated with TRM (RR5 1.0 [95%Days
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Figure 2. Cumulative incidence of CMV reactivation by GVHD pro-
phylaxis regimen. There is no significant difference between the ATG
containing regimen (CsA/methylprednisone/ATG) and the non-ATG
containing regimen (CsA/MMF).CI 0.5-1.8], P5 0.88), leukemia relapse (RR5 1.2
[95% CI 0.6-2.1], P5 .62), or OS (RR5 0.9 [95%
CI 0.6-1.5], P5 .78). In addition, CMV reactivation
was not associated with the development of aGVHD
(RR5 1.0 [95% CI 0.5-2.0], P5 .97) or cGVHD
(RR5 1.2 [95% CI 0.6-2.1], P5 .65) (Table 4).
CMV-seropositive recipients were also assessed
based on the number of CMV reactivation events post-
transplant. Eighty patients had 1 reactivation and 12
patients had 2 reactivations. The number of CMV re-
activations (1 versus 2) was not predictive of progres-
sion-free survival (PFS) (P5 .60), TRM (P5 .31), or
OS (P5 .31).
Of the CMV-positive recipients, 13.9% (25/180)
developed CMV disease involving the following sites:
respiratory (n5 16), GI (n5 6) or multiorgan
(n5 3). Among patients with CMV disease, TRM
was 48% (95% CI 27%-69%), aGVHD occurred in
17% (95% CI 0%-38%), cGVHD in 10% (95% CI
0%-22%), and OS was 43% (95% CI 23%-63%).
Comparing patients with CMV disease to those who
reactivated, but did not develop disease, there was in-
creased TRM (RR5 3.9 [95% CI 1.4-11.2], P5 .01)
and decreased OS (RR5 2.4 [95% CI 1.1-5.2],
P5 .02). The relative risk of relapse (RR5 1.3 [95%
CI 0.4-3.9], P5 .62) and cGVHD (RR 5 0.6 [95%
CI 0.1-2.6], P5 .51) were not significantly different
between patients with CMV reactivation who did
and did not develop CMV disease.DISCUSSION
We analyzed the impact of recipient CMV serosta-
tus and the consequences of CMV reactivation on
transplant-associated outcomes using 332 patients
with hematologic malignancies undergoing MA or
RIC followed by transplantation with either 1 or 2
UCB units. When compared to CMV seronegativeTable 3. Univariate Analysis of Pretransplant CMV Seros-
tatus and Transplant-Associated Outcomes
Variable CMV Serostatus at
Transplant All No. of Events 1 Year (Range) P
Overall survival .55
Negative 152 53 65% (57%-72%)
Positive 180 67 63 (55%-69%)
Disease relapse .78
Negative 152 43 28% (21%-35%)
Positive 180 51 28% (21%-35%)
Treatment-related mortality .07
Negative 152 24 16% (10%-22%)
Positive 180 43 24% (18%-30%)
Acute GVHD (Grade II-IV) Day 100 .80
Negative 152 77 51% (43%-59%)
Positive 180 84 47% (39%-55%)
Chronic GVHD .24
Negative 152 30 19% (13%-25%)
Positive 180 42 21% (15%-27%)
GVHD indicates graft-versus-host disease; CMV, cytomegalovirus.
Table 4. CMV Reactivation and Transplant-Related Outcomes
Variable All No. of Events 1 Year (Range) Relative Risk (95% CI) P
No CMV reactivation 1.0
CMV reactivation
Overall survival 92 32 64% (53%-73%) 0.9 (0.6-1.5) .78
Disease relapse 89 27 31% (21%-41%) 1.2 (0.6-2.1) .62
Treatment-related mortality 89 20 30% (20%-40%) 1.0 (0.5-1.8) .88
Acute GVHD (Grade II-IV) 56 12
Day 100
22% (11%-33%) 1.0 (0.5-2.0) .97
Chronic GVHD 89 20 22% (18%-30%) 1.2 (0.6-2.1) .65
GVHD indicates graft-versus-host disease; CMV, cytomegalovirus; CI, confidence interval.
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comes. CMV reactivation did not alter TRM, GVHD,
relapse, or survival; however, patients who developed
CMV disease had higher TRM and lower OS, but re-
lapse and cGVHD were unaffected.
Previous reports have found that CMV reactiva-
tion in the post-UCB setting varies between 21%
and 100% [11,31]. CMV reactivation after BM and
PB transplant have ranged from 12.8% to 22% in
study groups containing both CMV-seronegative and
-seropositive donors and recipients and 52% to 69%
in CMV-seropositive donors and recipients [11,32-
34]. The rate of CMV reactivation in this study was
51%, and there was no difference for patients undergo-
ing RIC or MA conditioning. We and others have
shown that the rate of CMV reactivation after UCB
transplantation is not different when compared to
more traditional hematopoietic cell sources such as
BM or PB [11,32-34].
To date, only 5 studies have focused on CMV
reactivation following UCB transplantation [3,11,31,
35,36]. The largest of these studies included 140 Japa-
nese adults, all of whom received RIC [3]. Similar to
our findings, CMV reactivation (antigenemia) oc-
curred in 55% of patients at a median of day 135.
These investigators observed that a low CD341 cell
dose was a risk factor for CMV reactivation. In con-
trast, we found no impact for either total mononuclear,
CD341 or CD31 cell dose on CMV reactivation.
Tomonari et al [36] evaluated 101 Japanese adults,
all of whom received MA conditioning. Sixty-five per-
cent of these patients had CMV reactivation. There
was no significant difference between CMV-seronega-
tive and CMV-seropositive patients with respect to
TRM, aGVHD and cGVHD, leukemia relapse, and
OS, similar to our findings.
Our findings show that CMV seropositivity
pretransplant and CMV reactivation do not have a
negative impact on transplant outcomes. This is in
contrast to prior studies where UCB transplant recip-
ients had inferior outcomes following CMV reactiva-
tion [3,8,31,37]. Although in our study TRM was not
significantly different between CMV-seronegative
and CMV-seropositive recipients, CMV-seropositiverecipients did show a trend toward greater day 100
TRM (P5 .07). Curiously, CMV reactivation was
not associated with higher TRM.
In this analysis, follow-up was limited to day1100
because patients are typically transitioned to their
home institution at that time. As a result, data regard-
ing CMV reactivation after this time point was not
available. However, late CMV reactivation is increas-
ingly being reported, and a recent study found late
CMV reactivation to be as high as 31% [38]. In addi-
tion, data for this study, including patient characteris-
tics and outcomes, was collected prospectively;
however the outcome analysis was done retrospec-
tively. Perhaps a larger prospective study that captures
late CMV reactivation events and progression to CMV
disease could help determine whether the trend toward
increased TRM among CMV seropositive recipients
becomes significant with longer follow-up. However,
a subset analysis of this study revealed very few CMV
reactivation events beyond day 1100 (not shown).
High-dose acyclovir prophylaxis, as used in this
study, has been shown to be equivalent to ganciclovir
in preventing CMV antigenemia and disease while
having a lower side effect profile with respect to neu-
tropenia and bacterial infections [39]. Prophylactic
ganciclovir has toxicities such as myelosuppression
and increased risk of infection [33]. Moreover, ganci-
clovir may cause delayed recovery of CMV-specific
T cell immunity, resulting in increased late CMV dis-
ease [40]. Perhaps the use of high-dose acyclovir pro-
phylaxis, rather than ganciclovir, had an impact on
the severity and consequence of CMV reactivation in
our patients.
We found that CMV disease developed in 13.8%
of CMV-seropositive patients and among 27.1% of
those who reactivated. These findings are similar to
previous UCB transplant studies that have reported
disease rates of 12% to 13% among seropositive
UCB recipients and 23% to 29% for patients with
CMV reactivation [3,11,14]. As would be expected,
we found a lower OS and higher TRM among
patients with CMV reactivation who experienced
disease compared to those who did not develop
CMV disease.
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sociated with GHVD [3,28,29], and the immune sup-
pression used for GVHD treatment may diminish
graft-versus-leukemia reactions. Interestingly, 2 re-
cent studies showed a reduction in leukemia relapse
rate in pediatric CMV seropositive donors and recipi-
ents, particularly in children where prophylaxis was
omitted and only preemptive therapy was used
[37,41]. There was no association between CMV and
GVHD or disease recurrence in our study; however,
we did not use the earlier approach.
ALC at day130 posttransplant is predictive of sur-
vival in patients with a number of malignant diseases
including acute lymphoblastic leukemia (ALL), acute
myelogenous leukemia (AML), multiple myeloma
(MM), Hodgkin disease (HD), and non-Hodgkin lym-
phoma (NHL) following autologous or allogeneic
transplantation [42-48]. Although studies have varied
in their ALC cutoff and day of analysis, patients with
low ALCs (\1.75-3.0 108/L) early after transplant
(days 121-30) showed inferior survival compared to
patients with higher ALCs [43-48]. In a subsequent
study, ALC\2.0 was found to be predictive of CMV
infection in adult UCBT patients in univariate analysis
[33]. In contrast, we found that an ALC\2.0 at day
128 was associated with a lower incidence of CMV re-
activation (37% versus 61%, P5 .02). However, the
competing risk of death among patients with ALC
\2.0 was much higher (27%) than that for patients
with ALC $2.0 (4%).
KIRs are a polymorphic family of surface receptors
expressed by NK cells and some T cells. Depending
upon the individual receptor, KIR can either positively
or negatively regulate lymphocyte activation and func-
tion. Individuals vary in the number of KIR genes con-
tained within their genome, and have been referred to
as either haplotype A or B, depending upon the relative
absence or presence of activating KIR, respectively
[49]. Prior studies show that donor KIR haplotype
may be associated with CMV reactivation. More spe-
cifically, recipients of HCT from a donor with a KIR
B/X haplotype [50] or those that express KIR2DS2
[51] have a decreased incidence of CMV reactivation.
In our study, donor KIR haplotype did not appear to
influence recipient CMV reactivation (P5 .83); how-
ever, KIR haplotype was only available for a subset of
patients.
In summary, we could not identify a relationship
between either CMV serostatus or reactivation follow-
ing UCBT and transplantation outcomes. As well, the
rate of CMV reactivation in this study is similar to that
reported for other HSC sources [11,32,34]. Further
studies are required to elucidate whether the trend
toward greater day 100 TRM among CMV seroposi-
tive recipients following UCB transplant reaches
significance, especially in the setting of late reactiva-
tion. Perhaps current CMV prophylaxis and vigilantpreemptive treatment strategies have reduced the his-
toric significance of pretransplant CMV serostatus for
most UCB transplant recipients, given the similar
TRM, relapse, OS, aGVHD, and cGVHD. However,
some patients still develop CMV disease, which
continues to be associated with higher TRM and
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